Mergers & Acquisitions - Pharmaceutical, Rare diseases

Filter

Popular Filters

Shire finally accepts AbbVie’s takeover offer

Shire finally accepts AbbVie’s takeover offer

18-07-2014

After a protracted and at times hostile courtship, Ireland-headquartered drugmaker Shire has finally…

AbbVieHumiraMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Shire confirms it has entered into talks with AbbVie

Shire confirms it has entered into talks with AbbVie

12-07-2014

Following reports by the Bloomberg news service, on Friday Ireland-based drugmaker Shire confirmed that…

AbbVieIrelandMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Shire acquires Lumena Pharma, adding to rare disease portfolio

Shire acquires Lumena Pharma, adding to rare disease portfolio

12-05-2014

Ireland-headquartered drugmaker Shire says it will acquire San Diego, USA-based rare disease focussed…

Lumena PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesShire

Riemser Pharma acquires French drugmaker Keocyt

12-05-2014

German specialty pharmaceutical company Riemser Pharma (formerly Riemser Arzneimittel) said today that…

KeocytMergers & AcquisitionsOncologyPharmaceuticalRare diseasesRiemser Pharma

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

16-04-2014

French orphan drug developer BioAlliance Pharma and Denmark’s Topotarget today announced their intention…

belinostatBioAlliance PharmaLivatagMergers & AcquisitionsOncologyPharmaceuticalRare diseasesTopotarget

Prothelia and Alexion partner with University of Nevada for ultra-rare neuromuscular disorder

Prothelia and Alexion partner with University of Nevada for ultra-rare neuromuscular disorder

17-02-2014

Privately-held USA-based Prothelia and the University of Nevada, Reno, have entered into strategic agreements…

Alexion PharmaceuticalsMergers & AcquisitionsPharmaceuticalProtheliaRare diseasesResearch

Retrophin to acquire Manchester Pharma in $62.5 million deal

Retrophin to acquire Manchester Pharma in $62.5 million deal

13-02-2014

USA-based Retrophin has signed an agreement to acquire Manchester Pharmaceuticals, a privately-held specialty…

Cardio-vascularChenodalManchester PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesRetrophinVecamyl

Forest Labs to spend $2.9 billion on acquiring Aptalis

Forest Labs to spend $2.9 billion on acquiring Aptalis

09-01-2014

Confirming recent speculative reports, US drugmaker Forest Laboratories says it has entered into a definitive…

AptalisForest LaboratoriesGastro-intestinalsMergers & AcquisitionsPharmaceuticalRare diseases

Italy’s Gentium accepts $1 billion takeover offer from Jazz Pharma

20-12-2013

Ireland-headquartered drugmaker Jazz Pharmaceuticals has entered into a definitive agreement to acquire…

defibrotideDefitelioGentiumItalyJazz PharmaceuticalsMergers & AcquisitionsNephrology and HepatologyPharmaceuticalRare diseases

Shire strengthens position in rare diseases with $4.2 billion buy of ViroPharma

Shire strengthens position in rare diseases with $4.2 billion buy of ViroPharma

11-11-2013

Ireland-based drugmaker Shire saw its share rise 2.2% to £33.16 shortly after markets opened this morning,…

CinryzeFirazyrMergers & AcquisitionsPharmaceuticalRare diseasesShireViroPharma

Salix Pharma moves into diabetes with $2.6 billion buy of Santarus

Salix Pharma moves into diabetes with $2.6 billion buy of Santarus

08-11-2013

Salix Pharmaceuticals has entered into a definitive merger agreement to acquire all the outstanding common…

DiabetesGastro-intestinalsGlumetzaMergers & AcquisitionsPharmaceuticalRare diseasesRuconestSalix PharmaceuticalsSantarus

Chiesi expands rare disease portfolio with acquisition

26-08-2013

Privately-owned Italian drugmaker Chiesi Group has signed, through its UK affiliate, a definitive agreement…

BiotechnologyChiesi FarmaceuticiLamazymMergers & AcquisitionsPharmaceuticalRare diseasesZymenex

Zambon to acquire UK respiratory specialist Profile Pharma

10-06-2013

Family-owned Italian drugmaker Zambon has taken a significant step to grow in the respiratory therapy…

Mergers & AcquisitionsPharmaceuticalProfile PharmaPromixinRare diseasesRespiratory and PulmonaryZambon

Shire acquires Premacure to expand in new therapy area

13-03-2013

In a second acquisition so far this year, Ireland-headquartered drugmaker Shire (LSE: SHP) said on Tuesday…

BiotechnologyMergers & AcquisitionsOphthalmicsPharmaceuticalPremacureRare diseasesShire

Shire to acquire Lotus Tissue Repair for undisclosed price

09-01-2013

Ireland-headquartered drugmaker Shire (LSE: SHP) said yesterday that it has signed an agreement to acquire…

BiotechnologyLotus Tissue RepairMergers & AcquisitionsPharmaceuticalRare diseasesShire

Recordati buys US portfolio of drugs from Lundbeck

17-12-2012

Italian drugmaker Recordati *RC: MI) has signed an agreement for the acquisition of all rights concerning…

LundbeckMergers & AcquisitionsNorth AmericaPharmaceuticalRare diseasesRecordati

Shire to acquire FerroKin BioSciences; drops Replagal BLA

16-03-2012

Ireland-headquartered Shire (LSE: SHP) said yesterday that it has signed an agreement to acquire privately-held…

FerroKin BioSciencesMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRare diseasesRegulationReplagalShire

Cushing’s syndrome patients to receive safer drug options

22-02-2012

New upcoming treatments for Cushing’s syndrome promise to improve patient’s quality of life,…

Corcept TherapeuticsHRA PharmaKorlymMergers & AcquisitionsMifedrenNovartisPharmaceuticalRare diseasesResearchSignifor

Alexion to buy Enobia Pharma for potential $1 billion

30-12-2011

US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) has reached agreement to acquire privately held Canadian…

Alexion Pharmaceuticalsasfotase alfaEnobia PharmaMergers & AcquisitionsPharmaceuticalRare diseases

ViroPharma buys option to acquire Meritage Pharma

28-12-2011

ViroPharma (Nasdaq: VPHM) has entered into an exclusive option to acquire fellow USA based Meritage Pharma,…

BudesonideMergers & AcquisitionsMeritage PharmaPharmaceuticalRare diseasesResearchViroPharma

Actelion pulls out of Trophos option

13-12-2011

Switzerland-based Actelion (SIX: ATLN), Europe’s biggest biotech company, says that it has decided…

ActelionBiotechnologyLicensingMergers & AcquisitionsolesoximePharmaceuticalRare diseasesTrophos

ViroPharma to acquire DuoCort Pharma for up to $164 million, adding European orphan drug to pipeline

28-10-2011

The USA’s ViroPharma (Nasdaq: VPHM) says it has signed a definitive agreement to acquire DuoCort…

DuoCort PharmaMergers & AcquisitionsPharmaceuticalPlenadrenRare diseasesViroPharma

Back to top